TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CFO James Emmett Young Acquires 24,000 Shares

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CFO James Emmett Young purchased 24,000 shares of the stock in a transaction dated Monday, January 27th. The shares were purchased at an average price of $5.40 per share, with a total value of $129,600.00. Following the completion of the acquisition, the chief financial officer now owns 24,000 shares of the company’s stock, valued at approximately $129,600. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

TriSalus Life Sciences Price Performance

NASDAQ:TLSI traded down $0.04 during trading hours on Wednesday, reaching $4.93. The company’s stock had a trading volume of 16,469 shares, compared to its average volume of 23,643. The business’s 50-day moving average is $4.55 and its 200-day moving average is $4.75. TriSalus Life Sciences, Inc. has a one year low of $3.50 and a one year high of $10.42. The company has a market cap of $150.32 million, a price-to-earnings ratio of -1.98 and a beta of 0.51.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Roth Capital raised shares of TriSalus Life Sciences to a “strong-buy” rating in a report on Monday, November 11th. Cantor Fitzgerald began coverage on TriSalus Life Sciences in a research report on Tuesday, December 17th. They set an “overweight” rating and a $10.00 price objective for the company. Northland Securities started coverage on shares of TriSalus Life Sciences in a report on Friday, October 25th. They issued an “outperform” rating and a $12.50 price objective for the company. Northland Capmk upgraded TriSalus Life Sciences to a “strong-buy” rating in a research report on Friday, October 25th. Finally, Canaccord Genuity Group reduced their target price on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a report on Friday, November 15th. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, TriSalus Life Sciences presently has an average rating of “Buy” and an average target price of $11.79.

Hedge Funds Weigh In On TriSalus Life Sciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC grew its position in TriSalus Life Sciences by 45.4% in the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock valued at $924,000 after acquiring an additional 62,542 shares during the period. MSD Partners L.P. bought a new stake in shares of TriSalus Life Sciences in the 3rd quarter valued at $184,000. Walleye Capital LLC acquired a new position in shares of TriSalus Life Sciences in the 3rd quarter valued at approximately $66,000. Virtu Financial LLC bought a new stake in TriSalus Life Sciences in the 3rd quarter valued at $92,000. Finally, Vestcor Inc bought a new stake in TriSalus Life Sciences during the 3rd quarter worth about $108,000. Institutional investors and hedge funds own 2.58% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.